FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019082937> ?p ?o ?g. }

• W2019082937 endingPage "695" @default.
• W2019082937 startingPage "687" @default.
• W2019082937 abstract "The retinoblastoma protein (pRB) is a key regulator of the G1 cell cycle checkpoint and has been implicated as having a role in G1 arrest and apoptosis induced by radiation damage. In this report we examine the association between pRB expression and radiation response in patients treated between 1960 and 1983 with preoperative radiotherapy (50 Gy in 25 fractions) followed 4-6 weeks later by radical cystectomy. The correlation of pRB to patient outcome and how this relationship is complimentary to that seen with p53 staining status is also described.Immunohistochemical staining of pRB and p53 in paraffin-embedded tumor sections using WL-1 anti-RB and DO1 anti-p53 antibodies was considered adequate in 98 and 97 pretreatment tumor samples, respectively. There were 46 patients with clinical Stage T2, 28 with Stage T3a, and 24 with Stage T3b disease. The median age was 62 years and follow-up for those living was 85 months.Staining for pRB was negative in 30% of the cases. Correlations were observed between pRB negativity and high pretreatment apoptosis level (p = 0.06), locally advanced clinical stage (p = 0.01), increased clinical-to-pathologic downstaging (p = 0.014), and more pathologic complete responses (Path-CRs; p = 0.019). Several other factors were tested and were not associated with pRB status, including p53 expression. RB status was the only pretreatment prognostic factor in the univariate analyses that correlated with downstaging and was independently associated with Path-CR using multivariate logistic regression. Despite these significant relationships, no correlations with patient outcome were observed when the entire cohort was analyzed. Restriction of the analyses to Stage T3b patients, however, revealed that pRB negativity predicted for enhanced distant metastasis freedom (p = 0.006, log rank) and overall survival (p = 0.02). The overexpression of p53 also correlated with distant metastasis freedom and overall survival in Stage T3b patients. Patient outcome was best when RB negative and p53 negative staining were seen.Our results indicate that loss of RB function as measured by immunohistochemical staining is the strongest correlate of radiation response thus far recognized. Loss of RB expression also predicted for poor outcome in Stage T3b patients, which appeared to compliment the finding of normal p53 expression. While normal RB protein expression is usually associated with better patient outcome, other series have not examined patients treated with radiotherapy. The absence of pRB may be a useful marker for selecting patients for bladder preservation with radiotherapy, particularly when wild-type p53 is present." @default.
• W2019082937 created "2016-06-24" @default.
• W2019082937 creator A5002737792 @default.
• W2019082937 creator A5025147400 @default.
• W2019082937 creator A5046668269 @default.
• W2019082937 creator A5054759359 @default.
• W2019082937 creator A5063389942 @default.
• W2019082937 creator A5064171627 @default.
• W2019082937 creator A5069116689 @default.
• W2019082937 creator A5074455927 @default.
• W2019082937 date "1997-10-01" @default.
• W2019082937 modified "2023-09-27" @default.
• W2019082937 title "Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer" @default.
• W2019082937 cites W1774531900 @default.
• W2019082937 cites W1975102863 @default.
• W2019082937 cites W1975172819 @default.
• W2019082937 cites W1979319210 @default.
• W2019082937 cites W1981391513 @default.
• W2019082937 cites W1983013270 @default.
• W2019082937 cites W1984557785 @default.
• W2019082937 cites W1987466655 @default.
• W2019082937 cites W1992773474 @default.
• W2019082937 cites W2002853354 @default.
• W2019082937 cites W2028522982 @default.
• W2019082937 cites W2045292004 @default.
• W2019082937 cites W2052268236 @default.
• W2019082937 cites W2053432671 @default.
• W2019082937 cites W2058774117 @default.
• W2019082937 cites W2089218510 @default.
• W2019082937 cites W2090831233 @default.
• W2019082937 cites W2095573751 @default.
• W2019082937 cites W2123449896 @default.
• W2019082937 cites W2152062168 @default.
• W2019082937 cites W2313608588 @default.
• W2019082937 cites W262237791 @default.
• W2019082937 cites W4245844897 @default.
• W2019082937 cites W91495214 @default.
• W2019082937 doi "https://doi.org/10.1016/s0360-3016(97)00147-8" @default.
• W2019082937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9336151" @default.
• W2019082937 hasPublicationYear "1997" @default.
• W2019082937 type Work @default.
• W2019082937 sameAs 2019082937 @default.
• W2019082937 citedByCount "32" @default.
• W2019082937 countsByYear W20190829372014 @default.
• W2019082937 countsByYear W20190829372015 @default.
• W2019082937 countsByYear W20190829372018 @default.
• W2019082937 countsByYear W20190829372019 @default.
• W2019082937 countsByYear W20190829372022 @default.
• W2019082937 crossrefType "journal-article" @default.
• W2019082937 hasAuthorship W2019082937A5002737792 @default.
• W2019082937 hasAuthorship W2019082937A5025147400 @default.
• W2019082937 hasAuthorship W2019082937A5046668269 @default.
• W2019082937 hasAuthorship W2019082937A5054759359 @default.
• W2019082937 hasAuthorship W2019082937A5063389942 @default.
• W2019082937 hasAuthorship W2019082937A5064171627 @default.
• W2019082937 hasAuthorship W2019082937A5069116689 @default.
• W2019082937 hasAuthorship W2019082937A5074455927 @default.
• W2019082937 hasConcept C104317684 @default.
• W2019082937 hasConcept C121608353 @default.
• W2019082937 hasConcept C126322002 @default.
• W2019082937 hasConcept C126894567 @default.
• W2019082937 hasConcept C142724271 @default.
• W2019082937 hasConcept C143998085 @default.
• W2019082937 hasConcept C144301174 @default.
• W2019082937 hasConcept C146357865 @default.
• W2019082937 hasConcept C151730666 @default.
• W2019082937 hasConcept C185592680 @default.
• W2019082937 hasConcept C190283241 @default.
• W2019082937 hasConcept C204232928 @default.
• W2019082937 hasConcept C2775910329 @default.
• W2019082937 hasConcept C2776062698 @default.
• W2019082937 hasConcept C2776577112 @default.
• W2019082937 hasConcept C2780352672 @default.
• W2019082937 hasConcept C29537977 @default.
• W2019082937 hasConcept C38180746 @default.
• W2019082937 hasConcept C509974204 @default.
• W2019082937 hasConcept C55493867 @default.
• W2019082937 hasConcept C71924100 @default.
• W2019082937 hasConcept C86803240 @default.
• W2019082937 hasConceptScore W2019082937C104317684 @default.
• W2019082937 hasConceptScore W2019082937C121608353 @default.
• W2019082937 hasConceptScore W2019082937C126322002 @default.
• W2019082937 hasConceptScore W2019082937C126894567 @default.
• W2019082937 hasConceptScore W2019082937C142724271 @default.
• W2019082937 hasConceptScore W2019082937C143998085 @default.
• W2019082937 hasConceptScore W2019082937C144301174 @default.
• W2019082937 hasConceptScore W2019082937C146357865 @default.
• W2019082937 hasConceptScore W2019082937C151730666 @default.
• W2019082937 hasConceptScore W2019082937C185592680 @default.
• W2019082937 hasConceptScore W2019082937C190283241 @default.
• W2019082937 hasConceptScore W2019082937C204232928 @default.
• W2019082937 hasConceptScore W2019082937C2775910329 @default.
• W2019082937 hasConceptScore W2019082937C2776062698 @default.
• W2019082937 hasConceptScore W2019082937C2776577112 @default.
• W2019082937 hasConceptScore W2019082937C2780352672 @default.
• W2019082937 hasConceptScore W2019082937C29537977 @default.
• W2019082937 hasConceptScore W2019082937C38180746 @default.
• W2019082937 hasConceptScore W2019082937C509974204 @default.

• next